Impact of sintilimab plus anlotinib on progression-free survival in advanced unresectable hepatocellular carcinoma

doi:10.4251/wjgo.v18.i8.119966

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 8

This Article

(17)

(0)

(165)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Oncol. Aug 15, 2026; 18(8): 119966
Published online Aug 15, 2026. doi: 10.4251/wjgo.v18.i8.119966

Table 1 Comparison of baseline data between the two groups of patients, n (%)

Index	Experimental group (n = 45)	Control group (n = 45)	χ²/t	P value
Gender			0.102	0.749
Man	34 (75.6)	33 (73.3)
Woman	11 (24.4)	12 (26.7)
Age (years, mean ± SD)	58.6 ± 8.2	59.3 ± 7.9	0.398	0.691
Child-Pugh classification of liver function			0.235	0.628
Class A	30 (66.7)	29 (64.4)
Class B	15 (33.3)	16 (35.6)
BCLC stage			0.189	0.664
B	17 (37.8)	16 (35.6)
C	28 (62.2)	29 (64.4)
ECOG score			0.124	0.725
0-1	37 (82.2)	36 (80.0)
2	8 (17.8)	9 (20.0)
Tumor size (cm, mean ± SD)	5.8 ± 1.6	6.0 ± 1.5	0.592	0.554
Pre-treatment AFP (ng/mL, mean ± SD)	386.5 ± 124.3	392.7 ± 118.9	0.236	0.814
Pre-treatment CA19-9 (ng/mL, mean ± SD)	89.6 ± 32.4	92.3 ± 30.7	0.408	0.684

AFP: Alpha-fetoprotein; CA19-9: Carbohydrate antigen 19-9; BCLC: Barcelona Clinical Stage of Liver Cancer; ECOG: Eastern Cooperative Oncology Group.

Full Size Table

Citation: Sheng C, Li H. Impact of sintilimab plus anlotinib on progression-free survival in advanced unresectable hepatocellular carcinoma. World J Gastrointest Oncol 2026; 18(8): 119966
URL: https://www.wjgnet.com/1948-5204/full/v18/i8/119966.htm
DOI: https://dx.doi.org/10.4251/wjgo.v18.i8.119966

Sheng C, Li H. Impact of sintilimab plus anlotinib on progression-free survival in advanced unresectable hepatocellular carcinoma. World J Gastrointest Oncol 2026; 18(8): 119966 [DOI: 10.4251/wjgo.v18.i8.119966]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.